Molecular response of human cervical and lumbar nucleus pulposus cells from degenerated discs following cytokine treatment by 援ъ꽦�슧 et al.
©FUNPEC-RP www.funpecrp.com.brGenetics and Molecular Research 12 (1): 838-851 (2013)
Molecular response of human cervical and
lumbar nucleus pulposus cells from degenerated
discs following cytokine treatment
J.Y. Park, Y.S. Yoon, H.S. Park and S.U. Kuh
Department of Neurosurgery, Spine and Spinal Cord Institute, 
College of Medicine Gangnam Severance Spine Hospital, 
Yonsei University, Seoul, Korea
Corresponding authors: S.U. Kuh / Y.S. Yoon
E-mail: kuhsu@yuhs.ac / ysyoon@yuhs.ac
Genet. Mol. Res. 12 (1): 838-851 (2013)
Received December 5, 2012
Accepted February 20, 2013
Published March 15, 2013
DOI http://dx.doi.org/10.4238/2013.March.15.4
ABSTRACT. We investigated the molecular response of degenerated 
human cervical and lumbar nucleus pulposus (NP) cells following 
cytokine treatment. Degenerated cervical and lumbar discs (8 
each) were obtained from patients who underwent discectomy for 
degenerative disc disease; NP cells were isolated and cultured. The 
mRNA expressions of aggrecan, alkaline phosphatase, type I collagen, 
type II collagen, osteocalcin, and Sox9 in the 2 groups were compared 
by real-time PCR, before and following treatment with rhBMP-2 and 
TGF-β1. Immunoreactivity was analyzed to check protein activity. 
Type I collagen expression was significantly higher in cervical 
compared with that in lumbar disc cells. The mRNA expression was 
significantly increased after rhBMP-2 and TGF-β1 treatment. After 
rhBMP-2 treatment, mRNA expression of type I and II collagens 
increased significantly more in cervical than in lumbar NP cells. 
Following TGF-β1 treatment, the increase in mRNA expression was not 
significantly different between cervical and lumbar disc cells. Protein 
immunoreactivity, before and after cytokine treatment was similar to 
mRNA expression data. The matrix-related gene expression of cervical 
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and lumbar NP after rhBMP-2 and TGF-β1 treatment increased 
similarly, with the exception of collagen expression.
Key words: Aggrecan; Alkaline phosphatase; Collagen; Osteocalcin; 
rhBMP-2; TGF-β1
INTRODUCTION
The pathogenesis of intervertebral disc degeneration is a complex process that dis-
rupts the well-defined organizational and biochemical balance due to replacement of the nor-
mal disc matrix by more fibrotic, less cartilaginous material (Antoniou et al., 1996a,b; Evans, 
2006; Peng et al., 2006; Yoon and Patel, 2006; Kuh et al., 2009; Park et al., 2011). Disc de-
generative changes can be associated with pain, and treatment options are limited. Many trials 
of potential molecular and biological therapies have been conducted in this context. Previous 
studies have evaluated 3 main biochemical changes in disc degeneration: 1) decreased matrix 
synthesis, 2) increased catabolism, and 3) change in growth factors and cytokines associated 
with altered disc cell phenotypes during aging and degeneration (Diefenderfer and Brighton, 
2000; Tim et al., 2003; Yoon and Patel, 2006; Zhao et al., 2007; Fassett et al., 2009; Kuh et al., 
2009). Of the various genes associated with matrix synthesis, type I and type II collagens (fi-
brillar molecules), aggrecan (consists of a core protein to which sulfated-glycosaminoglycans 
are attached), Sox9 (upregulates both aggrecan and type II collagen), osteocalcin, and alkaline 
phosphatase (markers of osteogenic genes) are important (Adam and Deyl, 1984; Diefenderfer 
and Brighton, 2000; Tim et al., 2003; Kuh et al., 2009).
To reverse the degenerative changes by altering disc matrix metabolism, many inves-
tigators have attempted molecular therapies, including the use of cellular components, matrix 
derivatives, and molecules influencing disc cell metabolism and phenotypes (Tim et al., 2003; 
Yoon et al., 2004; Seguin et al., 2005; Weiler et al., 2005; Yoon and Patel, 2006; Evans, 2006; 
Fei et al., 2006; Kuh et al., 2008; Park et al., 2011). Previous molecular therapy trials were 
typically conducted on lumbar discs (Tim et al., 2003; Yoon et al., 2004; Seguin et al., 2005; 
Weiler et al., 2005; Evans, 2006; Fei et al., 2006; Yoon and Patel, 2006; Kuh et al., 2008; 
Sheikh et al., 2009). This is the first comparative study of the molecular biological response 
to cytokine treatment in cervical versus lumbar discs. This study was conducted to investigate 
the molecular biological response of degenerated human cervical and lumbar nucleus pulposus 
(NP) cells when treated with morphogens (rhBMP-2, TGF-β1) that influence disc metabolism 
and phenotype, and to determine differences between degenerative cervical and lumbar discs.
MATERIAL AND METHODS
Clinical materials
Living degenerated disc specimens were obtained from 16 patients (8 cervical and 8 
lumbar disc samples) who underwent discectomy for degenerative disc disease unresponsive 
to conservative therapy. After dissecting the disc space, a rectangular cut around the annulus 
fibrosus was made with a sharp knife, and using pituitary forceps, the disc was removed with 
the annulus and NP en block. After confirming the margin of the annulus and nucleus, only the 
NP was excised for this study.
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MRI (Magneton Vision 1.5T, Siemens, Erlangen, Germany) was performed on all pa-
tients. The PACS software and a PACS workstation (Centricity 2.0, General Electric Medical 
Systems, Milwaukee, WI, USA) were used to classify disc degeneration by an independent 
neurosurgeon and neuroradiologist not involved in the treatment. Disc degeneration was grad-
ed using routine T2-weighted MR images by the Pfirrmann grading system (Pfirrmann et al., 
2001). Only Pfirrmann grades IV and V were included in this study. This study was approved 
by the Institutional Review Board (IRB) of Gangnam Severance Hospital, Yonsei University 
College of Medicine (No. 3-2010-0008).
Isolation of disc cells and culture
All reagents were purchased from GibcoBRL (Grand Island, NY, USA). During lum-
bar discectomy, intervertebral disc materials were excised, and as mentioned above, disc tis-
sues were acquired from the nucleus pulposus and not from the annulus to ensure sample ho-
mogeneity. Tissues were dissected into small pieces and incubated in 5% CO2/95% room air at 
37°C in Dulbecco’s modified Eagle’s medium and in Ham’s F-12 (DMEM/F-12) medium. To 
isolate nucleus pulposus cells, tissues were digested in DMEM/F-12 medium containing 0.2% 
protease (Sigma Chemical, St. Louis, MO, USA) for 1 h, followed by 0.025% collagenase 
(Sigma) for 12 h. Cells passaged no more than twice were used in the subsequent experiments.
NP (3 x 104 cells/well) were grown as monolayer cultures for 6 days in DMEM/F-12 
medium containing 10% fetal bovine serum (FBS), 10 U/mL penicillin, 10 µg/mL streptomy-
cin, and 0.2 mM L-glutamine. Primers to detect the mRNA expression of aggrecan, alkaline 
phosphatase, type I collagen, type II collagen, osteocalcin, and Sox9 were then constructed 
using complete mRNA sequences obtained from the National Center for Biotechnology In-
formation. The forward and reverse primer sequences of all genes examined in this study are 
summarized in Table 1.
 Primer Sequence (5'→3')
1. Aggrecan Forward CTGCTTCCGAGGCATTTCAG
 Reverse CTTGGGTCACGATCCACTCC
2. Alkaline phosphatase Forward ATGGGATGGGTGTCTCCACA
 Reverse CCACGAAGGGGAACTTGTC
3. Type I collagen Forward GTCGAGGGCCAAGACGAAG
 Reverse CAGATCACGTCATCGCACAAC
4. Type II collagen Forward GGTCTTGGTGGAAACTTTGCT
 Reverse GGTCCTTGCATTACTCCCAAC
5. Osteocalcin Forward CACTCCTCGCCCTATTGGC
 Reverse CCCTCCTGCTTGGACACAAAG
6. Sox9 Forward AGCGAACGCACATCAAGAC
 Reverse GCTGTAGTGTGGGAGGTTGAA
7. GAPDH* Forward ATGGGGAAGGTGAAGGTCG
 Reverse GGGGTCATTGATGGCAACAATA
*GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as a house keeping gene.
Table 1. Primer sequences.
Treatment with cytokines
NP in each experimental group were cultured on a 6-well plate in an incubator (5% 
CO2/95% room air at 37°C) at 3 x 10
4 cells/well. When the cells were confluent, the medium 
was replaced with DMEM/F-12 medium containing 1% FBS for starvation, 10 U/mL penicil-
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lin, 10 µg/mL streptomycin, 0.2 mM L-glutamine, and 5 µg/mL vitamin C. Gene expression 
levels after each treatment with 2 morphogens (rhBMP-2 and TGF-β1) were analyzed using 
real-time PCR (RT-PCR). The mRNA expression levels in cervical and lumbar NP cultures 
without cytokine treatment were compared and used as a baseline control according to the 
treatment group. NP were grown as a monolayer and treated with 100 ng/mL rhBMP-2 (R&D 
System, Minneapolis, MN, USA) or 10 ng/mL TGF-β1 (Invitrogen, Carlsbad, CA, USA) for 
6 days. On day 3, the culture medium was changed while maintaining the same concentration 
of rhBMP-2 and TGF-β1 in each well.
RT-PCR assay
An ABI StepOnePlus (Applied Biosystems, Foster city, CA, USA) system that detects 
SYBR green fluorescent dye incorporated in double-stranded DNA was used for analysis. 
The 20-µL reaction mixture contained 200 ng cDNA (obtained by RT-PCR) and 5 pmol each 
primer (aggrecan, alkaline phosphatase, type I collagen, type II collagen, osteocalcin, or 
Sox9). Forty RT-PCR cycles were performed for denaturation (95°C for 30 s), annealing, and 
elongation (60°C for 60 s). To confirm amplification specificity, PCR products were subjected 
to melting curve analysis. Threshold cycles (CT) for the genes analyzed were normalized to 
glyceraldehyde phosphate dehydrogenase (GAPDH) expression. The mRNA expression levels 
in cervical and lumbar disc tissues are reported as a ratio (cervical/lumbar).
Immunofluorescence staining with antibodies
NP cells (3 x 104 cells/well) were grown as monolayer cultures in DMEM/F-12 medium 
containing 1% FBS, 10 U/mL penicillin, 10 µg/mL streptomycin, 0.2 mM L-glutamine, and 5 μg/
mL vitamin C. The cultured cells were fixed with 100% EtOH and then washed with 10 mM PBS 
(Sigma). Monoclonal anti-aggrecan, anti-alkaline phosphatase, anti-type I collagen, anti-type II 
collagen, anti-osteocalcin, and anti-Sox9 antibodies were applied respectively at 4°C overnight. 
After washing, secondary antibody conjugated with fluorescein isothiocyanate (FITC) was ap-
plied to the wells. The immunoreactivity of intervertebral disc cells for rhBMP-2 and TGF-β1 
were analyzed to check the chondrogenic activity. The wells were then rinsed, mounted and 
photographed using a fluorescence photomicroscope (NIKON Microphot-SA, Japan). For im-
munofluorescence, fluorochromes on the sections were excited using a 510-nm emission filter 
for green fluorescent protein, and a 580-nm emission filter for secondary antibody with FITC.
Statistical analysis
Intergroup comparisons were made using the Wilcoxon signed-rank test and the 
Mann-Whitney test. P < 0.05 was considered to be statistically significant. All analyses were 
carried out using SPSS ver. 15.00 (SPSS, Inc., Chicago, IL, USA).
RESULTS
Patient characteristics
Degenerated cervical and lumbar discs (Pfirrmann grades IV and V) were obtained 
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from 16 patients who underwent discectomy for degenerative disc disease. Discs were al-
located to two groups: cervical disc (Pfirrmann grade IV/V; 5/3 patients) and lumbar disc 
(Pfirrmann grade IV/V; 5/3 patients). There was no statistical difference in age between the 
cervical (53.4 ± 15.7 years) and lumbar disc (56.9 ± 15.8 years) groups.
Quantitation of mRNA levels
We assayed the mRNA levels of aggrecan, alkaline phosphatase, type I collagen, type 
II collagen, osteocalcin, and Sox9. The mean values and standard deviations of all parameters 
studied are listed in Table 2. Baseline mRNA gene expression levels by Cт mean in cervical 
and lumbar NP cells without cytokine treatment were not statistically different except for type 
I collagen. mRNA expression in the lumbar discs was significantly higher for type I collagen 
(1.53-fold) than in cervical discs (Table 2 and Figure 1; P < 0.05). The mRNA levels of ag-
grecan, alkaline phosphatase, type II collagen, osteocalcin, and Sox9 tended to be higher in 
lumbar discs (Figure 1).
     Cervical                  Lumbar
 RQ ±SD Cт ±SD ΔCт ±SD ΔΔCт ±SD RQ ±SD Cт ±SD ΔCт ±SD ΔΔCт ±SD
   mean  mean      mean  mean
Aggrecan without  1.00 - 27.06 2.68   6.36 3.54 - - 1.00 - 35.03 6.43 5.49 5.21 - -
   cytokines
Aggrecan with rhBMP-2 3.33 0.94 25.15 3.01   4.68 3.31 -1.69 0.39 2.50 0.58 33.21 6.15 4.20 5.20 -1.29 0.34
Aggrecan with TGF-β1 2.80 0.87 25.05 3.36   4.94 3.59 -1.42 0.46 2.14 0.51 32.89 6.44 4.43 5.17 -1.06 0.36
Alkaline phosphatase  1.00 - 30.78 3.09   9.69 1.90 - - 1.00 - 35.85 5.05 6.30 4.51 - -
   without cytokines
Alkaline phosphatase  2.77 0.74 28.22 2.01   8.26 1.99 -1.42 0.38 2.78 0.72 33.87 4.86 4.86 4.37 -1.44 0.33
   with rhBMP-2
Alkaline phosphatase  2.32 1.04 28.52 2.00   8.57 1.90 -1.12 0.54 2.16 0.37 33.67 4.83 5.21 4.65 -1.09 0.25
   with TGF-β1
Type I collagen without  1.00 -   20.96† 2.74  -1.62 4.93 - - 1.00 -   31.99† 7.52 2.45 3.87 - -
   cytokines
Type I collagen with    2.90* 1.17 18.66 1.63  -3.07 5.27 -1.44 0.55 1.87 0.38 30.58 7.24 1.57 3.86 -0.88 0.29
   rhBMP-2
Type I collagen with  2.67 1.14 18.65 2.13  -2.92 4.95 -1.30 0.64 2.38 1.10 29.76 7.26 1.30 3.79 -1.15 0.57
   TGF-β1
Type II collagen without  1.00 - 31.96 3.75   9.97 3.56 - - 1.00 - 36.07 2.49 6.52 6.42 - -
   cytokines
Type II collagen with    3.52* 0.81 29.53 2.77   8.19 3.49 -1.78 0.32 2.53 0.37 34.20 2.56 5.19 6.40 -1.33 0.20
   rhBMP-2
Type II collagen with  2.43 0.76 29.91 3.54   8.76 3.59 -1.21 0.50 2.71 0.87 33.61 2.46 5.15 6.64 -1.37 0.48
   TGF-β1
Osteocalcin without  1.00 - 32.83 1.58 11.30 4.14 - - 1.00 - 35.91 3.31 6.37 5.86 - -
   cytokines
Osteocalcin with  2.30 0.98 31.35 1.23 10.21 4.38 -1.09 0.61 2.57 1.09 34.12 3.26 5.11 5.51 -1.26 0.56
   rhBMP-2
Osteocalcin with TGF-β1 1.97 0.59 31.12 1.18 10.37 4.18 -0.93 0.42 2.06 0.80 33.85 3.02 5.39 5.57 -0.97 0.45
Sox9 without cytokines 1.00 - 26.61 2.76   5.92 2.53 - - 1.00 - 33.28 5.83 3.73 1.71 - -
Sox9 with rhBMP-2 2.27 0.54 25.24 3.46   4.77 2.57 -1.15 0.35 2.41 0.60 31.51 5.82 2.50 1.59 -1.24 0.31
Sox9 with TGF-β1 2.34 0.53 24.84 3.20   4.73 2.49 -1.19 0.35 2.27 0.58 30.93 5.43 2.47 2.08 -1.13 0.44
RQ = relative quantification; SD = standard deviation; CT = threshold cycle. †P < 0.05 for cervical vs lumbar 
disc without cytokine treatment. *P < 0.05 for cervical vs lumbar disc after cytokine treatment. Significance was 
assessed using the Mann-Whitney U-test.
Table 2. mRNA expression after cytokine treatment compared to groups without treatment.
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After rhBMP-2 and TGF-β1 treatment, mRNA levels by relative quantification (RQ) 
of aggrecan, alkaline phosphatase, type I collagen, type II collagen, osteocalcin, and Sox9 
were statistically increased in cervical and lumber discs when compared to groups without 
treatment (Tables 2 and 3; Figure 2; P < 0.01). Following rhBMP-2 treatment, mRNA expres-
sion of type I collagen (RQ for cervical/lumbar: 2.90/1.87) and type II collagen (RQ for cervi-
cal/lumbar: 3.52/2.53) demonstrated significant differences between cervical and lumbar discs 
with higher expression in the cervical discs (Tables 2 and 3; Figure 2; P < 0.05). The mRNA 
levels of aggrecan, alkaline phosphatase, osteocalcin, and Sox9 were not statistically different 
(Tables 2 and 3; Figure 2). Following TGF-β1 treatment, mRNA levels of aggrecan, alkaline 
phosphatase, type I collagen, type II collagen, osteocalcin, and Sox9 were not statistically dif-
ferent between cervical and lumbar discs (Tables 2 and 3; Figure 2).
Figure 1. Threshold cycle (CT) mean ratio between lumbar and cervical disc cells (lumbar/cervical) for mRNA 
levels of aggrecan, alkaline phosphatase, type I collagen, type II collagen, osteocalcin, and Sox9 without cytokine 
treatment. *P < 0.05 between cervical and lumbar comparisons.
                        Cervical                           Lumbar
                        rhBMP-2                         TGF-β1                          rhBMP-2                           TGF-β1
   RQ ±SD RQ ±SD   RQ ±SD RQ ±SD
Aggrecan 3.33 0.94 2.80 0.87 2.50 0.58 2.14 0.51
Alkaline phosphatase 2.77 0.74 2.32 1.04 2.78 0.72 2.16 0.37
Type I collagen   2.90* 1.17 2.67 1.14   1.87* 0.38 2.38 1.10
Type II collagen   3.52* 0.81 2.43 0.76   2.53* 0.37 2.71 0.87
Osteocalcin 2.30 0.98 1.97 0.59 2.57 1.09 2.06 0.80
Sox9 2.27 0.54 2.34 0.53 2.41 0.60 2.27 0.58
RQ = relative quantification; SD = standard deviation. *P < 0.05 for cervical vs lumbar disc after cytokine treatment. 
Significance was assessed using the Mann-Whitney U-test.
Table 3. mRNA expression after cytokine treatment compared to groups without treatment.
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Immunofluorescence reactivity
The average numbers of immunofluorescence-positive cells for all proteins are listed 
in Table 4. The protein immunoreactivity of aggrecan, alkaline phosphatase, type I collagen, 
type II collagen, osteocalcin, and Sox9, with and without cytokine, also showed similar re-
sults as mRNA expression. After rhBMP-2 and TGF-β1 treatment, the average numbers of 
immunofluorescence-positive cells for aggrecan, alkaline phosphatase, type I collagen, type II 
collagen, osteocalcin, and Sox9 were increased in cervical (Figure 3) and lumbar discs (Figure 
4) when compared to groups without treatment (Table 4).
Figure 2. mRNA level ratios between groups without treatment and with cytokine treatment by relative quantification 
(RQ). The mRNA levels of aggrecan, alkaline phosphatase, type I collagen, type II collagen, osteocalcin, and Sox9 
with cytokine (rhBMP-2, TGF-β1) treatment were assayed in cervical and lumbar disc cells. *P < 0.01 between groups 
without treatment and with cytokine treatment. **P < 0.05 between cervical and lumbar after rhBMP-2 treatment.
                                 Cervical                                 Lumbar
 Cell numbers ±SD Cell numbers ±SD
Aggrecan without cytokines 17.00 12.33   7.00   1.63
Aggrecan with rhBMP-2 77.25 13.60 28.00 11.17
Aggrecan with TGF-β1 44.00 12.91 13.50   2.65
Alkaline phosphatase without cytokines 30.50 12.87 10.75   4.86
Alkaline phosphatase with rhBMP-2 68.50 10.85 20.50   9.68
Alkaline phosphatase with TGF-β1 50.50 22.66 15.50   6.61
Type I collagen without cytokines 21.00   0.82   4.25   1.50
Type I collagen with rhBMP-2 67.25   8.26 16.75   9.43
Type I collagen with TGF-β1 47.25 13.45   8.25   3.50
Type II collagen without cytokines 35.25 15.84   6.50   3.11
Type II collagen with rhBMP-2 84.50 23.25 13.75   1.89
Type II collagen with TGF-β1 57.75   9.74 15.00   8.29
Osteocalcin without cytokines 22.25   5.56   4.00   2.16
Osteocalcin with rhBMP-2 48.50 16.13 12.50   1.73
Osteocalcin with TGF-β1 38.50 20.70   7.25   1.89
Sox9 without cytokines 39.00 24.68   3.00   2.16
Sox9 with rhBMP-2 61.00 13.19 10.75   3.30
Sox9 with TGF-β1 67.00 12.83   8.00   3.37
Table 4. Average number of immunofluorescence-positive-stained cell.
SD = standard deviation.
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1
2
3
Figure 3. Immunostaining of human intervertebral disc cells for aggrecan (1), alkakine phosphatase (2), type I 
collagen (3), type II collagen (4), osteocalcin (5), and Sox9 (6) in cervical disc in controls (A) and after rhBMP-2 
(B), and TGF-β1 treatment (C).
Continued on next page
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Figure 3. Continued.
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Figure 4. Immunostaining of human intervertebral disc cells for aggrecan (1), alkaline phosphatase (2), type I 
collagen (3), type II collagen (4), osteocalcin (5), and Sox9 (6) in lumbar disc in controls (A) and after rhBMP-2 
(B) and TGF-β1 treatment (C).
1
2
3
Continued on next page
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Figure 4. Continued.
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DISCUSSION
Human beings have had back pain throughout recorded history, but not neck pain, so 
disc treatments usually focus on lumbar rather than cervical discs (Waddell, 1996; Feuerstein 
et al., 2004; Sobajima et al., 2008; Genevay et al., 2009; Kuh et al., 2008, 2009; Park et al., 
2011). In the current study, differences between cervical and lumbar disc degeneration at the 
gene expression level were investigated. The purpose of the current study was to investigate 
and compare the expression of matrix-associated genes in cervical and lumbar discs when 
degenerative changes have occurred and to compare responses following cytokine treatment. 
The results of the current study indicate that cervical and lumbar discs have similar 
gene expression patterns in living degenerated human discs. A prior study by Scott et al. 
(1994) reported that the collagen content of the NP was highest in cervical discs and lowest in 
lumbar discs (Longo et al., 2006). The reason cervical discs have more collagen than lumbar 
discs may be that the cell number is much greater in cervical discs or that gene expression 
is higher in cervical discs. The current results suggest that cervical collagen genes are more 
actively expressed than in lumbar discs in a similar degenerative state.
This study also attempted to address whether there are differences between cervi-
cal and lumbar discs in response to molecular treatment. Following rhBMP-2 and TGF-β1 
treatment, mRNA levels of aggrecan, alkaline phosphatase, type I collagen, type II collagen, 
osteocalcin, and Sox9 were statistically increased in both cervical and lumbar discs. Molecular 
therapies for disc degeneration have been devised based on phenotypic changes in degener-
ated discs (Yoon and Patel, 2006). In general, four different classes of molecules are currently 
being investigated: anti-catabolics, mitogens, morphogens, and intracellular regulators (Tim 
et al., 2003; Yoon et al., 2004; Seguin et al., 2005; Weiler et al., 2005; Evans, 2006; Fei et al., 
2006; Yoon and Patel, 2006; Kuh et al., 2008; Park et al., 2011). However, molecular therapy 
trials have been conducted on individual candidates and only at one location among the cervi-
cal, thoracic, and lumbar discs (Tim et al., 2003; Yoon et al., 2004; Seguin et al., 2005; Weiler 
et al., 2005; Evans, 2006; Fei et al., 2006; Yoon and Patel, 2006; Kuh et al., 2008; Sheikh et 
al., 2009). This is the first study to compare responses to molecular therapies between cervical 
and lumbar disc cells. Following rhBMP-2 treatment, mRNA expression of type I and II colla-
gens was significantly different between cervical and lumbar disc cells, with cervical disc cells 
demonstrating higher gene expression. The mRNA levels of aggrecan, alkaline phosphatase, 
osteocalcin, and Sox9 were not statistically different for cervical versus lumbar discs.
When comparing baseline gene expression without cytokine treatment, we can con-
clude that collagen gene expression is more active in cervical disc cells than in lumbar disc 
cells, with or without treatment. Although many anatomic differences exist between the cervi-
cal and lumbar spine, differences in collagen gene expression may be associated with a lower 
rate of neck pain compared with back pain. However, there were no statistical differences in 
mRNA expression for all matrix-associated genes between the cervical and lumbar disc cells 
following TGF-β1 treatment. This suggests that matrix-associated gene responses can differ 
according to molecular therapy. From the current study, we conclude that the general response 
to molecular therapy in cervical and lumbar discs is similar, and that a healthy disc at either 
location can be used for cell transplantation therapy to other discs. As an example, less degen-
erated cervical nucleus pulposus cells could be transplanted to a lumbar disc after culture for 
disc therapy.
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This study has several limitations that require consideration. The sample size was small 
and only focused on matrix-associated genes. Various pro-inflammatory cytokines (TNF-α, 
IL-1β, IL-6, IL-1α, nitric oxide, and prostaglandin E2, among others) are upregulated during 
disc degeneration (Yoon and Patel, 2006; Zhao et al., 2007; Rutges et al., 2008; Fassett et 
al., 2009; Millward-Sadler et al., 2009). To determine the exact differences between cervical 
and lumbar disc degeneration, studies including these pro-inflammatory cytokines are 
required. Additionally, only two morphogens (rhBMP-2 and TGF-β1) were studied. Athough 
rhBMP-2 and TGF-β1 are the most commonly used morphogens in molecular therapy for disc 
regeneration, different classes of molecules are also being investigated, namely, anti-catabolics, 
mitogens, morphogens, and intracellular regulators (Tim et al., 2003; Yoon et al., 2004; Seguin 
et al., 2005; Weiler et al., 2005; Evans, 2006; Yoon and Patel, 2006; Fei et al., 2006; Kuh et al., 
2008; Park et al., 2011). Further study with various treatment molecules is needed to adequately 
compare responses to molecular therapy between cervical and lumbar discs.
In spite of these limitations, our results demonstrate that degenerated cervical and lum-
bar disc cells have similar gene expression patterns during degeneration, with the exception of 
type I collagen. Additionally, collagen gene expression is also associated with differences in 
molecular therapy response between cervical and lumbar discs. In general, cervical and lumbar 
discs demonstrated a similar degenerative pattern and similar molecular therapy responses.
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